Summit Therapeutics (SMMT)
(Delayed Data from NSDQ)
$3.86 USD
+0.31 (8.73%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.86 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.86 USD
+0.31 (8.73%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.86 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Zacks News
Summit Therapeutics PLC (SMMT) Moves 17.4% Higher: Will This Strength Last?
by Zacks Equity Research
Summit Therapeutics PLC (SMMT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Summit Therapeutics (SMMT) Surges: Stock Moves 7.2% Higher
by Zacks Equity Research
Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
New Strong Sell Stocks for October 30th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Summit Therapeutics PLC (SMMT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Summit Therapeutics PLC (SMMT) closed at $3.75, marking a +1.08% move from the previous day.
Is Summit Therapeutics (SMMT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (SMMT) Outperforming Other Medical Stocks This Year?
Summit Therapeutics PLC (SMMT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Summit Therapeutics PLC (SMMT) closed at $4.20 in the latest trading session, marking a +1.94% move from the prior day.
Summit Therapeutics PLC (SMMT) Stock Moves -0.43%: What You Should Know
by Zacks Equity Research
In the latest trading session, Summit Therapeutics PLC (SMMT) closed at $3.48, marking a -0.43% move from the previous day.
Will Ventilator Sales Drive Medtronic's (MDT) Q4 Earnings?
by Zacks Equity Research
Medtronic (MDT) might have registered lower demand for its emergency procedures in Q4 with patients trying to avoid any non-COVID-19 emergency treatment.
CytoDyn (CYDY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On CytoDyn's (CYDY) upcoming earnings call, investor focus will be on the updates related to its CCR5 antagonist candidate, leronlimab, which is being developed for multiple therapeutic indications.
Is Summit Therapeutics (SMMT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (SMMT) Outperforming Other Medical Stocks This Year?
Summit Therapeutics PLC (SMMT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Summit Therapeutics PLC (SMMT) closed the most recent trading day at $3.11, moving +0.33% from the previous trading session.
Is Summit Therapeutics (SMMT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (SMMT) Outperforming Other Medical Stocks This Year?
Summit Therapeutics PLC (SMMT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Summit Therapeutics PLC (SMMT) closed the most recent trading day at $3.68, moving +0.55% from the previous trading session.
Summit Therapeutics (SMMT) Catches Eye: Stock Jumps 8.9%
by Zacks Equity Research
Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Here's Why Momentum Investors Will Love Summit Therapeutics PLC (SMMT)
by Zacks Equity Research
Does Summit Therapeutics PLC (SMMT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Summit Therapeutics (SMMT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (SMMT) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: DHT, Summit Therapeutics, Sharps Compliance, Frontline and Kala Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: DHT, Summit Therapeutics, Sharps Compliance, Frontline and Kala Pharmaceuticals
5 Stocks Up on Signs of Slowdown in Coronavirus Cases
by Zacks Equity Research
Coronavirus shows signs of slowdown in the United States and some other countries. While investors look for positive developments in the stock market, here are five must-buy stocks poised to grow.
Top Ranked Momentum Stocks to Buy for April 7th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 7th
Top Ranked Momentum Stocks to Buy for March 26th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 26th
Top Ranked Momentum Stocks to Buy for March 25th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 25th
Is Summit Therapeutics (SMMT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (SMMT) Outperforming Other Medical Stocks This Year?
Summit Therapeutics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Summit Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
Can the Rally in Summit Therapeutics Shares Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Summit Therapeutics.
Top Ranked Momentum Stocks to Buy for October 22nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 22nd